These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38958494)

  • 1. Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0.
    Chan C; Jansen JHM; Hendriks IST; van der Peet IC; Verdonschot MEL; Passchier EM; Tsioumpekou M; Nederend M; Klomp SA; Valerius T; Peipp M; Leusen JHW; Olofsen PA
    Mol Cancer Ther; 2024 Sep; 23(9):1317-1331. PubMed ID: 38958494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.
    Stip MC; Evers M; Nederend M; Chan C; Reiding KR; Damen MJ; Heck AJR; Koustoulidou S; Ramakers R; Krijger GC; de Roos R; Souteyrand E; Cornel AM; Dierselhuis MP; Jansen M; de Boer M; Valerius T; van Tetering G; Leusen JHW; Meyer-Wentrup F
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37479484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Effector Functions of Human IgG2 Antibodies against EGFR.
    Rösner T; Kahle S; Montenegro F; Matlung HL; Jansen JHM; Evers M; Beurskens F; Leusen JHW; van den Berg TK; Valerius T
    Mol Cancer Ther; 2019 Jan; 18(1):75-88. PubMed ID: 30282813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
    Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
    Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.
    Brandsma AM; Ten Broeke T; Nederend M; Meulenbroek LA; van Tetering G; Meyer S; Jansen JH; Beltrán Buitrago MA; Nagelkerke SQ; Németh I; Ubink R; Rouwendal G; Lohse S; Valerius T; Leusen JH; Boross P
    Cancer Immunol Res; 2015 Dec; 3(12):1316-24. PubMed ID: 26407589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity.
    Derer S; Glorius P; Schlaeth M; Lohse S; Klausz K; Muchhal U; Desjarlais JR; Humpe A; Valerius T; Peipp M
    MAbs; 2014; 6(2):409-21. PubMed ID: 24492248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing IgA-mediated neutrophil cytotoxicity against neuroblastoma by CD47 blockade.
    Chan C; Stip M; Nederend M; Jansen M; Passchier E; van den Ham F; Wienke J; van Tetering G; Leusen J
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering Dimeric EGFR-directed IgA Antibodies Reveals a Central Role of CD147 during Neutrophil-mediated Tumor Cell Killing of Head and Neck Squamous Cancer Cells.
    Zwick A; Braun FL; Weber LJ; Linder M; Linxweiler M; Lohse S
    J Immunol; 2024 Jul; 213(2):148-160. PubMed ID: 38787053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.
    Heemskerk N; Gruijs M; Temming AR; Heineke MH; Gout DY; Hellingman T; Tuk CW; Winter PJ; Lissenberg-Thunnissen S; Bentlage AE; de Donatis M; Bögels M; Rösner T; Valerius T; Bakema JE; Vidarsson G; van Egmond M
    J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33561014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.
    Liu Z; Gunasekaran K; Wang W; Razinkov V; Sekirov L; Leng E; Sweet H; Foltz I; Howard M; Rousseau AM; Kozlosky C; Fanslow W; Yan W
    J Biol Chem; 2014 Feb; 289(6):3571-90. PubMed ID: 24311787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgA EGFR antibodies mediate tumour killing in vivo.
    Boross P; Lohse S; Nederend M; Jansen JH; van Tetering G; Dechant M; Peipp M; Royle L; Liew LP; Boon L; van Rooijen N; Bleeker WK; Parren PW; van de Winkel JG; Valerius T; Leusen JH
    EMBO Mol Med; 2013 Aug; 5(8):1213-26. PubMed ID: 23918228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
    J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
    Gerdes CA; Nicolini VG; Herter S; van Puijenbroek E; Lang S; Roemmele M; Moessner E; Freytag O; Friess T; Ries CH; Bossenmaier B; Mueller HJ; Umaña P
    Clin Cancer Res; 2013 Mar; 19(5):1126-38. PubMed ID: 23209031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells.
    Schlaeth M; Berger S; Derer S; Klausz K; Lohse S; Dechant M; Lazar GA; Schneider-Merck T; Peipp M; Valerius T
    Cancer Sci; 2010 May; 101(5):1080-8. PubMed ID: 20331636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity.
    Elter A; Yanakieva D; Fiebig D; Hallstein K; Becker S; Betz U; Kolmar H
    Front Immunol; 2021; 12():715719. PubMed ID: 34413859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells.
    Grugan KD; Dorn K; Jarantow SW; Bushey BS; Pardinas JR; Laquerre S; Moores SL; Chiu ML
    MAbs; 2017 Jan; 9(1):114-126. PubMed ID: 27786612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
    Zhang D; Goldberg MV; Chiu ML
    J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy.
    Bedi A; Chang X; Noonan K; Pham V; Bedi R; Fertig EJ; Considine M; Califano JA; Borrello I; Chung CH; Sidransky D; Ravi R
    Mol Cancer Ther; 2012 Nov; 11(11):2429-39. PubMed ID: 22927667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.